Background Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia
of unknown cause that is associated with radiological and/or histological features of usual …

Introduction Idiopathic pulmonary fibrosis (IPF) is a severe interstitial lung disease for which
two effective antifibrotics, nintedanib and pirfenidone, are available. However, many patients …

Background Pirfenidone and nintedanib are the sole pharmacological therapies currently
approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in …

Background Pirfenidone and nintedanib are the only disease-modifying treatments available
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …

Background: Two therapeutic options are currently available for patients with mild-to-
moderate idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. To date, there is …

Background The antifibrotic drugs nintedanib and pirfenidone reduce disease progression
in idiopathic pulmonary fibrosis (IPF) and have also shown to improve survival. Switching …

Background Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2–5
years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression …

Background Real-life data on the use of pirfenidone and nintedanib to treat patients with
idiopathic pulmonary fibrosis (IPF) are still scarce. Methods We compared the efficacy of …

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic,
progressive scarring of the lungs and the pathological hallmark of usual interstitial …

Introduction The antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary
fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real …